No quarterly revenue total was found in Trevi Therapeutics, Inc.'s SEC filings.
Trevi Therapeutics, Inc. (TRVI) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$17.6 million. As of Jun 30, 2026 it held $318.9 million in cash and investments and $605,000 in total debt.
Revenue
—
Net income
$-17.80M
-44.7% vs year-ago quarter
Operating cash flow
$-17.43M
-72.5% vs year-ago quarter
Free cash flow
$-17.55M
-73.8% vs year-ago quarter
EPS
$-0.11
-22.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
142.48M
+17.0% vs year-ago quarter
Net cash
$318.26M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TRVI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1563880
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$20.5M | -$14.9M | -$10.2M | -$13.9M | -$13.7M |
| Net income | -$17.8M | -$13.2M | -$8.3M | -$11.8M | -$12.3M |
| Diluted EPS | -$0.11 | -$0.09 | -$0.06 | -$0.08 | -$0.09 |
| Operating cash flow | -$17.4M | -$16.7M | -$7.6M | -$10.9M | -$10.1M |
| Free cash flow | -$17.6M | -$16.8M | -$7.6M | -$10.9M | -$10.1M |
| Total assets | $330.5M | $179.6M | $193.4M | $199.4M | $208.3M |
| Total liabilities | $9.0M | $7.5M | $10.2M | $9.6M | $9.8M |
| Stockholders' equity | $321.5M | $172.1M | $183.2M | $189.8M | $198.5M |
| Cash and investments | $318.9M | $171.8M | $188.3M | $194.9M | $203.9M |
| Total debt | $605,000 | $682,000 | $753,000 | $823,000 | $891,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 5, 2026 | May 5, 2026 |
| ARS | Annual report to shareholders | Apr 21, 2026 | Dec 31, 2025 |
All 537 Trevi Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.